Authors
Latest:
A Risk-Reward Reset: Getting Serious About Social MediaAs the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
Latest:
The Surprising Inefficiency of Field DeploymentsDeployments are often built on the concept that growth comes from new prescribers, which may be limiting their success.
Latest:
FDA Inspection and Enforcement Developments During the COVID-19 PandemicMitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
Latest:
Patient-First Approach Ensures People With Rare Disorders Receive Better Care and OutcomesImproving the patient experience for those with orphan diseases through a patient-first approach.
Latest:
Proactive Engagement: How AI-Driven Alerts are Transforming HCP OutreachThe benefits for brand teams in bolstering their rapid-response capability.
Latest:
2021 Will Be Another Transformative Year for Digital MarketingWhile COVID-driven challenges remain many, so do the carryover opportunities to redefine HCP engagement and communication.
Latest:
Building Effective Real World Evidence Studies to Support New Indications for Established ProductsThe use of real-world evidence can prevent pharma companies from performing studies based on flawed data.
Latest:
The Agile Future of Medical Information: Meeting 21st-Century Demands for HealthcareCOVID-19 pandemic has accelerated raised expectations for medical information professionals.
Latest:
Operating Models for Successful DOL EngagementHow life sciences companies can design an effective operating model for DOL engagements.
Latest:
Viable Options: Packaging and Partnering for Successful Storage and Transport of Conventional Cold-Chain Vaccines for Covid-19***Live: Thursday, February 25, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET*** As strategic planning among manufacturers and logistics partners commences, this webinar will serve as a platform to discuss service offerings and explore the most effective possible solutions. *** On demand until Feb. 25, 2022***
Latest:
HEOR: From Proving Product Value to Proving Its Own WorthThe recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.
Latest:
Supporting Successful Pharma Leadership with Neuroscience-Based LearningTo effectively lead in today’s unpredictable environment, several major pharma companies are turning to a neuroscience-based learning approach to leadership development.
Latest:
No Half Measures: How Medical Affairs Can Maximize and Measure ValueEducation and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
Latest:
How to Enhance DEI in Clinical TrialsIntegrating DEI strategies into clinical trials is both crucial for advancing biomedical knowledge and for bolstering trust and equitability within underrepresented communities.
Latest:
Inclusion Check-In: Who are You Giving Your Energy To?Three simple ways to build trust—by reaching outside your comfort zone.
Latest:
Developing Data Literacy with Training SimulationsIn order to address data literacy gaps amongst reps and managers, sales trainers are increasingly turning to computer-based business simulation games, writes Jeremy Lovelace.
Latest:
Creating Influence and Authority in Value-Based HealthcareWe may be only at the beginning of outcome-measured, value-based healthcare, but this is a chance for pharma organizations to show their mettle as roles are redefined and definitions of ‘value’ are agreed, says Gérard Klop of Vintura.
Latest:
Getting ‘Personal’ With Vaccine DevelopmentInnovative and continuous remote patient monitoring, along with AI-based predictive analytics, are advancing progress toward replacing the one-size-fits-all, population-driven vaccination model.
Latest:
Investing for Success: Finding the Right Launch BalanceChallenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Latest:
Bringing Data to Life: How Tech-Savvy Life Sciences Companies Can Better Serve the Healthcare SectorGoing beyond traditional market segmentation to understand the technological and data analytics capacity of target customers.
Latest:
The JAKs Journey Offers Valuable Lessons for InnovatorsOpportunity remains despite regulatory and access obstacles.
Latest:
No Half Measures: How Medical Affairs Can Maximize and Measure ValueEducation and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
